Claritin reditabs vs. Clarinex-d 12 hour: side effect and effectiveness comparison - a phase IV clinical study

Summary:

We compare the side effects and drug effectiveness of Claritin reditabs and Clarinex-d 12 hour. The phase IV clinical study is created by eHealthMe based on reports (from sources including the FDA) of 125,284 people who take Claritin reditabs and Clarinex-d 12 hour, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Sep, 28, 2022

125,284 people who take Claritin reditabs and Clarinex-d 12 hour are studied.


What is Claritin reditabs?

Claritin reditabs has active ingredients of loratadine. It is often used in allergies. eHealthMe is studying from 2,193 Claritin reditabs users for its effectiveness, alternative drugs and more.

What is Clarinex-d 12 hour?

Clarinex-d 12 hour has active ingredients of desloratadine; pseudoephedrine sulfate. It is often used in allergies. eHealthMe is studying from 64 Clarinex-d 12 hour users for its effectiveness, alternative drugs and more.

Number of reports submitted per year:

Claritin reditabs vs Clarinex-d 12 hour drug comparison reports.

Drugs being compared in this study:

  • Clarinex-D 12 Hour (desloratadine; pseudoephedrine sulfate)
  • Claritin Reditabs (loratadine)

Most common side effects of the drugs, overall:

Click here to view

Most common side effects of the drugs, in long term (1+ years) use:

Click here to view

Drug effectiveness:

Claritin Reditabs:
  • not at all: 2.32 %
  • somewhat: 22.85 %
  • moderate: 39.16 %
  • high: 27.5 %
  • very high: 8.18 %
Clarinex-D 12 Hour:
  • not at all: 0 %
  • somewhat: 14.63 %
  • moderate: 34.15 %
  • high: 31.71 %
  • very high: 19.51 %

Want to compare Claritin reditabs with Clarinex-d 12 hour?

Personalize this study to your gender and age (0-99+).

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of:

Common Claritin reditabs side effects:

How the study uses the data?

The study is based on loratadine and desloratadine; pseudoephedrine sulfate (the active ingredients of Claritin reditabs and Clarinex-d 12 hour, respectively). Other drugs that have the same active ingredients (e.g. generic drugs or brand names) are also considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: